

(19) **DANMARK**

(10) **DK/EP 2538986 T3**



(12) **Oversættelse af  
europæisk patentskrift**

Patent- og  
Varemærkestyrelsen

- 
- (51) Int.Cl.: **A 61 L 27/26 (2006.01)** **A 61 L 27/20 (2006.01)** **A 61 L 27/38 (2006.01)**  
**A 61 L 27/52 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2015-03-02**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2014-12-03**
- (86) Europæisk ansøgning nr.: **11702660.9**
- (86) Europæisk indleveringsdag: **2011-02-11**
- (87) Den europæiske ansøgnings publiceringsdag: **2013-01-02**
- (86) International ansøgning nr.: **EP2011052020**
- (87) Internationalt publikationsnr.: **WO2011104133**
- (30) Prioritet: **2010-02-25 EP 10154712**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Université de Liège, Interface Entreprises Université , Antheunis Nicole , Avenue Pré-Aily, 4, 4031 Angleur (Liege), Belgien**  
**Kitozyme S.A., Parc Industriel des Hauts Sarts, Zone 2 , Rue Haute Claire 4, 4040 Herstal, Belgien**
- (72) Opfinder: **HENROTIN, Yves, Aux Grands Champs 63, B-4052 Baufays, Belgien**  
**SANCHEZ, Christelle, Sur les Charneux 382, B-4870 Fraipont, Belgien**  
**OPRENYESZK, Frédéric, Rue Adolphe Marquet 11, B-4680 Hermee, Belgien**  
**DRION, Pierre, Saint Germain 14A, B-4860 Soiron, Belgien**
- (74) Fuldmægtig i Danmark: **Denemeyer & Associates S.A, Bavariastr. 7, D-80336 München, Tyskland**
- (54) Benævnelse: **INTRAARTIKULÆRT SUPPLEMENT TIL ANVENDELSE TIL BEHANDLING AF LEDSYGDOMME OG -SKADER**
- (56) Fremdragne publikationer:  
**WO-A1-2007/135114**  
**US-A1- 2004 047 912**  
**US-A1- 2006 280 797**  
**SEDA TÄ+-Ä LÄ+- R ET AL: "Evaluation of alginate-chitosan semi IPNs as cartilage scaffolds", JOURNAL OF MATERIALS SCIENCE: MATERIALS IN MEDICINE, KLUWER ACADEMIC PUBLISHERS, BO, vol. 20, no. 3, 6 November 2008 (2008-11-06), pages 699-709, XP019680168, ISSN: 1573-4838**  
**BARUCH, L.; MACHLUF, M.: "Alginate-Chitosan Complex Coacervation for Cell Encapsulation: Effect on Mechanical Properties and on Long-Term Viability", BIOPOLYMERS, vol. 82, 21 March 2006 (2006-03-21), pages 570-579, XP002593055,**



**Description****Field of the invention**

5 [0001] The present invention relates to a method of producing spherical hydrogel beads comprising a mixture of chitosan and alginate.

[0002] The present invention also relates to a supplement for treating joint disorders, particularly osteoarthritis.

**Background of the invention**

10

[0003] Osteoarthritis (OA) is a progressive degenerative disorder accompanied by pain and characterized by a breakdown of cartilage in articular joints, a deterioration of the synovial fluid present in the articular joints, and a resulting osteosclerosis.

[0004] Osteoarthritis increases with age, with a probability higher than 60% of those 60 years old or older.

15

[0005] Today, to remediate to the mechanical pain accompanied with OA, the present therapy is generally, either therapeutic with administration of analgesic or anti-inflammatory agents or a surgical therapy with partial or total joint replacement. An alternative approach is viscosupplementation which is an injection into the joint of a biocompatible viscous (e.g. Hyaluronic acid) lubricant that reduces friction and pain.

[0006] Viscosupplementation is used to supplement synovial fluid that lubricates and protects the articular joints. Indeed, in OA patient, the synovial fluid is modified with a decrease of concentration and molecular weight (Mw) of hyaluronan (or salt of hyaluronic acid HA).

20

[0007] Intra-articular injections comprising high molecular weight of HA preparations are currently available and used to treat knee, hip, carpometacarpal joint of the thumb or ankle. These preparations require one (Durolane™, Q-Med AB, Uppsala, Sweden), three (Synvisc®, high molecular weight cross-linked HA, Orthovisc®) to five (Hyalgan®, Supartz®) intra-articular (IA) injections (1 to 3 ml containing 5 to 20 mg/ml HA per injection according the joint).

25

**Table 1: Hyaluronic acid (HA) preparations**

Trade name	Corporation	Average Mw (kD)
Synvisc® (Hylan G-20)	Biomatrix (Canada)	6.000-7.000
Healon®	Pharmacia/ Upjohn (Sweden)	1.900-3900
Orthovisc®	Anika (USA)	1.700-2.900
Arthrum®	LCA (France)	2.000
Adant®	Meiji Seika (Japan)	900-1.200
SupArtz®, Artz®, Artzal®	Seikagaku (Japan)	600-1.200
Ostenil®	Chemedica (France)	1.200
Hyalgan®	Fidia (Italy)	500-730
Durolane™	Q-Med AB (Sweden)	≥ 9000

30

35

40

45 [0008] HA preparations vary in a number of characteristics, including for example, the source of HA (animal-derived or bacterial), the concentration and Mw of HA and the type and degree of chemical crosslinking used, if any. Usually, most injectable HA preparations, once injected, have residence half-life between hours to several days.

[0009] Several studies have compared the efficacy of the above-mentioned products and differently concluded to a marked reduction of pain and improved function of patients with knee OA. Some concluded that at best there is small effect compared to placebo injection. Others observed that 3-5 weekly injections of one of the above products, significantly improved the pain and functional status of patients with OA and that, although the onset of improvement was delayed by 3-4 weeks, the effect can last at least six months and up after treatment cessation. Other observed beneficial effects on OA symptoms, not only for knee OA but also for ankle or carpometacarpal joint of the thumb OA, but also adverse effects.

50

[0010] Moreover, clinical effect may be rapid at 1 week and may last for six months or more, but in all cases, multiple injections are essential for a prolonged (six month to one year) effect on osteoarthritic pain primarily because of the short residence half-life of most HA preparations.

55

[0011] Endly, WO2007/135114 describes viscosupplementation with polysaccharides compositions of a mixture of alginate and chitosan without generating insoluble coacervates. Coacervates are due to the polycationic nature of

chitosan that makes compatibility difficult with other polysaccharides such as hyaluronic acid (a polyanion) or alginate. According to WO2007/135114, precipitation/coacervation of polysaccharides such as chitosan and alginate prevents any formulation thereof as an injectable composition.

5 [0012] In WO2007/135114 a composition with an aqueous mixture of chitosan of a high degree of derivatization of at least 40% and an alginate is therefore described as highly viscous without generating insoluble coacervates.

[0013] A continued need exists to develop new intra-articular supplement product that protect cartilage against mechanical strains, provide effective relief to OA patient without necessitating multiple injections and to avoid adverse effect.

10 [0014] We have now found a new method of producing a homogenous hydrogel matrix comprising alginate and chitosan wherein chitosan is of low molecular weight and coacervates. The resulting alginate/chitosan beads obtainable by the new method remain surprisingly homogenous and stable when used for intra-articularly supplementation.

[0015] We have now found a new method and composition for single intra-articular supplementation of chitosan/alginate beads with a long-term residence (at least two weeks) in the joint without increasing viscosity of the synovial fluid.

[0016] The foregoing summary and the following description are not restrictive of the invention as claimed.

## 15 SUMMARY OF THE INVENTION

[0017] One aspect of the present invention relates to a method of producing a hydrogel matrix comprising the steps of:

- providing a solution of alginate,
- 20 - providing a solution with chitosan having a Mw between lower than 60 kDa,
- mixing the solution of alginate and the solution of chitosan, wherein the mixed solution comprises between 0.5 and 0.7 % (w/v) of chitosan and between 1 and 1.4 % alginate (w/v),
- introducing droplets of the mixed solution into a solution with Ca<sup>2+</sup> or Sr<sup>2+</sup> cations and
- isolating gellified beads from the solution with cations.

25 [0018] In certain embodiments of methods of the present invention, the droplets of the mixed solution are introduced in a solution of Sr<sup>2+</sup> ions.

[0019] In particular embodiments of this method the mixed solution comprises 0.6 % chitosan and or comprises 1.2 % alginate.

30 [0020] In particular embodiments of methods of the present invention the ratio between alginate and chitosan in the mixed solution is between 1.4 and 2.8, or between 1.75 and 2.25 or is about 2.

[0021] In particular embodiments of methods of the present invention the chitosan has a Mw of between 35 and 45 kDa and/or is of animal or preferably of vegetable origin.

35 [0022] In other particular embodiments of methods of the present invention, the method further comprises the step of mixing the beads in a thermosensitive hydrogel. Herein the ratio between beads and hydrogel is for example between 5/1 and 1/1, or between 4/1 and 2/1.

[0023] In other particular embodiments of methods of the present invention the formation of beads is performed by passing droplets through a needle to obtain beads with a diameter between 0.01 and 5 mm.

40 [0024] Another aspect of the present invention refers to a spherical hydrogel bead comprising a homogeneous mixture of chitosan and alginate, wherein said bead is obtainable by the methods as described above.

[0025] Another aspect of the present invention refers to a spherical hydrogel bead with a diameter between 0.01 and 5 mm, comprising a homogeneous mixture of chitosan and alginate, characterised in that the bead comprises between 1 and 1.4 % alginate and between 0.5 and 0.7 % chitosan, for example, the bead comprises 1.2 % alginate, or for example the bead comprises 0.6% chitosan.

45 [0026] In particular embodiments of beads of the present invention, the ratio of alginate/chitosan is between 1.4 and 2.8, preferably between 1.75 and 2.25, most preferably between 1.8 and 2.2.

[0027] In other particular embodiments of beads of the present invention the chitosan has a Mw between 35 and 45 kDa and/or is of animal or vegetable origin.

50 [0028] The invention also relates to an intra-articular supplement comprising spherical hydrogel beads with a diameter between 0.01 and 5 mm, comprising a homogeneous mixture of alginate and chitosan of Mw lower than 60 kDa, characterised in that said beads comprise between 1 and 1.4 % alginate and between 0.5 and 0.7 % chitosan.

[0029] The intra-articular supplement may further comprise a viscous thermogelling gel as for example a polysaccharide hydrogel, particularly a chitosan hydrogel.

55 [0030] By polysaccharides, one means biopolymers such as hyaluronic acid known as having repeating disaccharide units composed of glucuronic and N-acetylglucosamine, alginates and chitosan.

[0031] Chitosan is a polysaccharide widely available in nature obtained by chemical deacetylation of chitin and the principal constituent of crustacean exoskeletons but also from the mushrooms wall. It is composed of D-glucosamine units and N-acetyl-D-glucosamine units.

[0032] The intra-articular supplement may also comprise a component selected from the group consisting of non-steroidal anti-inflammatory drug, anaesthetic, opioid analgesics, corticosteroids, antineoplastic, monoclonal antibodies, chimeric monoclonal antibodies, vitamins, minerals, nutraceuticals.

5 [0033] The intra-articular supplement may also contain additional active or inactive components including for example, the non-steroidal anti-inflammatory drugs (NSAIDS) e.g diclofenac<sup>TM</sup>, ibuprofen<sup>TM</sup>, piroxicam<sup>TM</sup>; anesthetics, e.g. Lidocaine<sup>TM</sup> and Bupivacaine<sup>TM</sup>; opioid analgesics, e.g codeine and morphine; corticosteroids, e.g., dexamethasone and prednisone; antineoplastic agents such as Methotrexate<sup>TM</sup>; anti-viral agents, e.g. Acyclovir<sup>TM</sup> and Vidarabine<sup>TM</sup>; monoclonal antibodies e.g.Humira<sup>TM</sup> and chimeric monoclonal antibodies e.g infliximab<sup>TM</sup>. Intra-articular injectable supplements may also contain components such as cells, protein, DNA, minerals e.g selenium, strontium, vitamins e.g

10 tocopherol, nutraceuticals e.g.curcumin or other desirable biologically active material.

[0034] The inventive hydrogel beads described in claim 8 are used in a supplement for treating joint disorders of a subject, and for reducing pain and discomfort associated with joint injury or joint diseases including osteoarthritis and traumatic cartilage lesions.

15 [0035] Example of such joint diseases include osteoarthritis (primary (idiopathic) or secondary), rheumatoid arthritis, joint injury (e.g.traumatic or repetitive motion injury), cartilage pathology (e.g. chondrocalcosis, chondromalacia), septic arthritis. The inventive supplement is also for use in reducing pain associated with such diseases, to repair bone and cartilage lesion and to slow down disease progression.

[0036] The supplement may be formulated to provide for a single or multiple intra-articular injections or for implantation of the supplement in an amount sufficient to provide a therapeutic effect.

20 [0037] The intra-articular injection or implantation is done directly in bone and/or cartilage defect of human or non-human mammals for example by arthroscopy or with an injection device such as a syringe.

[0038] Examples of administration sites include the knee, shoulder, ankle, temporo-mandibular and carpo-metacarpal joints, elbow, hip, wrist, intervertebral disc.

25 [0039] The invention further provides a supplementation device comprising a pre-filled, single use syringe having a single dose of the supplements.

#### Brief description of the figures :

[0040]

30

Figure 1 shows beads obtained according to the method of the invention

Figure 2 shows a section of an alginate bead (A) and a chitosan/alginate bead (B) [chitosan: dark grey trabeculae; alginate: light grey background].

35

Figure 3 shows at low magnification chitosan/alginate beads embedded in a chitosan hydrogels

Figure 4 shows the implantation of a thermosensitive chitosan hydrogel comprising 0.6 % chitosan/1.2 %alginate beads (A. *bisporus* chitosan (40 kD))

40

Figure 5 shows the histological evaluation of the implant 15 days after implantation.

A: Subchondral Bone; B: Cell-colonized hydrogel; C: cell colonized Chitosan/alginate bead; D: Cell embedded in chitosan lacunae.

#### 45 Detailed description of the invention

[0041] One aspect of the present invention relates to a method of producing a hydrogel matrix. This method comprises the following steps:

- 50
- providing a solution of alginate,
  - providing a solution of chitosan with a Mw lower than 60kDa,
  - mixing the solution of alginate and the solution of chitosan , wherein the mixed solution comprises between 0.5 and 0.7 % (w/v) of chitosan and between 1 and 1.4 % alginate,
  - introducing droplets of the mixed solution into a solution with Ca<sup>2+</sup> or Sr<sup>2+</sup> ions
- 55
- isolating gellified beads from the solution with cations.

[0042] The hydrogel which is obtained by this method results in a homogeneous matrix of calcium alginate and chitosan.

[0043] The matrix as obtained in the present invention differs from prior art matrices which have a core of one com-

ponent, coated with a layer of another component.

[0044] The matrix as obtained in the present invention has the advantage that the porosity of the matrix can be more accurately defined compared to matrices which are first lyophilised to obtain a certain degree of porosity.

[0045] The matrix as obtained in the present invention has the advantage to be composed with a low molecular weight chitosan particularly between 15 and 50 kDa which spontaneously forms an homogenous network in the alginate matrix.

[0046] As indicated in the examples section, the alginate and chitosan which are used to prepare the hydrogels are dissolved in strong alkaline or acidic buffers which have a sterilising effect. This is an additional advantage of the present invention.

[0047] In the methods in accordance with the present invention the alginate and chitosan solutions can be mixed to obtain beads with different concentrations. Particular embodiments of the present invention relate to beads wherein the composition, prior to the gelification by calcium or strontium ions comprises 0.4, 0.45, 0.5, 0.55, 0.60, 0.65, 0.70, 0.75 or 0.80 % (w/v) chitosan, and independently thereof comprises 0.9, 0.95, 0.1, 0.105, 0.11, 0.115, 0.12, 0.125, 0.13, 0.135, 0.14, 0.145 or 1.5 % (w/v) alginate. In particular embodiments the concentration of chitosan ranges from 0.5 to 0.7 %, or from 0.55 to 0.65 %. In other particular embodiments the concentration of alginate ranges from 1. to 1.4 % or from 1.25 to 1.35 %. A particular embodiment of hydrogel comprises about 0.6 % chitosan and about 1.2 % alginate.

[0048] Further embodiments of methods and compositions of the present invention relate to hydrogel composition and beads obtained thereof wherein the ratio between alginate and chitosan in the mixed solution is between 1.4 and 2.8, more particularly between 1.5 and 2.7, more particularly between 1.6 and 2.6, or between 1.75 and 2.25. Particular values of this ratio are about 1.9, 1.95, 2.0, 2.05 and 1.

[0049] In the methods of the present invention the average size of the beads can be adapted and empirically determined by adjusting the diameter of the needle which is used to form the droplets which are introduced into the calcium or strontium solution. Envisaged herein are beads with a diameter between 0.01 and 5 mm. These dimensions provide a compromise between the ease of manipulation and the diffusion of nutrients into the beads.

[0050] The chitosan from the present invention may be isolated from different animal sources such as crustaceans (prawn shells) or squids. Alternatively the chitosan may be of vegetal, more of particularly fungal origin, such as *Mucoralean* strains, *Mucor racemosus* and *Cunninghamella elegans*, *Gongronella butleri*, *Aspergillus niger*, *Rhizopus oryzae*, *Lentinus edodes*, *Pleurotus sajocaju*, *Zygosaccharomyces rouxii*, *Candida albicans* or *Agaricus bisporus*.

[0051] Chitosan further exists in diverse types of molecular weight. Herein, the chain length of chitosan may contribute to the three dimensional structure of the hydrogels. Typical chitosans, for use in the present invention can have an average molecular weight between 15 and 50 kDa, more particularly between 35 and 45 kDa.

[0052] The method of manufacturing beads as described above, results in the formation of spherical hydrogel beads which comprise a homogeneous mixture of chitosan and alginate.

[0053] In particular embodiments, supplements are formulated as a biphasic supplement material formed by beads and a viscous gel. This supplement includes a polymeric matrix ("gel"), and the spherical three-dimensional beads comprising chitosan and alginate.

[0054] This allows to formulate an implantable or injectable gel which upon implantation, ensures an optimal space distribution in the host tissue or organ. The gel which is typically used herein in the supplement together with the beads prepared by the method of the invention, is a thermo-sensitive gel. These gels remain liquid at ambient temperature (in a device used for introduction in to the patient), but become solid upon introduction into the body at about 37°C. This in situ gelification maintains the beads in their spatial distribution. In vitro tests have demonstrated that beads were homogeneously distributed in such a hydrogel when heated to 37°C. Examples of thermosensitive hydrogels include poly(N-isopropylacrylamide (PNIPAAm). A particular type hereof is chitosan.

[0055] Without being bound by theory it is believed that the chitosan network within the microbeads confers particular mechanical properties at the beads such that they are less compressible and more resistant to pressure than the beads made of alginate only. The matrices of the present invention provide inter-connected chitosan trabeculae within an alginate gel, resulting in an environment which is favourable for cellular culture by providing an aqueous medium with a neutral pH.

[0056] Such trabeculae are obtained by insoluble chitosan which forms coacervates which create a basket-like structure network or trabeculae when mixed with alginate. The trabeculae are of varying thickness and length and provide to the beads particular biological and mechanical properties such as phenotype stabilisation, deformability, elasticity and compressive modulus.

## Examples

### Example 1. Preparation of alginate/chitosan beads

[0057] Beads are prepared from a homogeneous mixture of chitosan (0.6 % final) and alginate (1.2 % final). The two solutions are prepared separately before being mixed. The solutions of alginate and chitosan are prepared in the following

way: An alginate solution 2.4 % (W/v) in 0.16 M NaOH and a solution of chitosan 1.333 % (w/v) in 1.666 M HAc are prepared. To 10 volumes of the alginate solution, 1 volume of a 1M Hepes (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) solution is added. After homogenization, 9 volumes of chitosan solution are progressively added, while mixing regularly and vigorously. The chitosan/alginate solution is slowly passed through a 25 gauges needle in a dropwise fashion into a 102 mM CaCl<sub>2</sub> solution (Sigma-Aldrich, Bornem, Belgium). After instantaneous gelation, the beads are allowed to gellify further for 10 min in this CaCl<sub>2</sub> solution. At microscopic scale, the chitosan (stained in red by the eosin) forms a basket-like structure, composed of trabeculae or fibres of varying thickness and length (see figure 2 and 3). The interstices herein are filled by alginate (hematoxylin stained in violet).

#### 10 Example 2. Formulation of beads in a thermosensitive hydrogel.

[0058] The beads are mixed with a vegetable (*Agaricus bisporus*) chitosan hydrogel (Kitozyme, Alleur, Belgium]. This step is performed below 27°C to avoid hydrogel gelification. A ratio of beads/hydrogel of 3/1 (v/v) has been used.

#### 15 Example 3. Implantation in an animal model

[0059] A gel as described under example 2, has been implanted in a rabbit with subchondral bone and cartilage defect joint. (Figure 4).

[0060] After 15 days of implantation, the implant was evaluated (Figure 5 ). The lesion remains filled with the implant. Beads and viscous hydrogel remain constant at least two weeks after injection in the injured joint, while maintaining a safety profile.

[0061] Further it is observed that the implant is colonised with cells originating from the underlying bone marrow. Cells were encountered in the settled thermosensitive chitosan hydrogel (B) as well as in the chitosan alginate beads (C) (chitosan trabeculae are indicated by D). This test confirms that the biphasic implant can be easily handled and grafted. The biodegradable nature of the implant ensures a progressively resorption after implantation.

#### Example 4. Effect of chitosan molecular weight in beads formation.

[0062] Different molecular weights of native chitosan have been used in the process according to the invention. Different physical parameters such as pH and viscosity of the mixed solution (with chondrocytes were measured., Osmolarity of the resulting hydrogel is measured according to a well-known technique in the art.

Table 1

Solutions	pH	Viscosity (Cps)	Osmolarity (mOsm/kg)
Alginate 1.2% / chitosan 22 kDa 0.6%	7.8	110.7	324
Alginate 1.2% / chitosan 30 kDa 0.6%	8.3	230	305
Alginate 1.2% / chitosan 32 kDa 0.6%	7.8	192	308
Alginate 1.2% / chitosan 55 kDa 0.6%	8.0	279	290
Alginate 1.2% / chitosan 55 kDa 0.6%	8.2	336	302
Alginate 1.2% / chitosan 91 kDa 0.6%	Impossible to mix		
Alginate 1.2% / chitosan 146 kDa 0.6%	Impossible to mix		

[0063] We concluded that mixed beads can be made with native chitosan below 55 kDa. For example, at 91 kDa, beads cannot be made using the process described in our invention and at the ratio alginate 1.2% and chitosan 0.6%, the chitosan solution is too viscous. Therefore, the selection of chitosan molecular weight is an essential element in our invention.

**Example 5:** A supplementation method for treating an articular joint of a human subject or an animal with a needle.

[0064] A needle has been used to deliver the intra-articularly supplement. For intra-articular administration, supplement is delivered in the synovial cavity at a density of 1,000 to 20,000 beads of 0.1 to 0.5 μm per ml in a volume of approximately 1-2 ml per injection. For example, 1 ml of physiological liquid containing 10,000 beads of 0,2 μm is injected into a knee joint using a fine (e.g. 14-22 gauge, preferably 18-22 gauges) needle.

[0065] Example 6: A supplementation method for treating an articular joint of a human subject or an animal with a trochar

[0066] A trochar has been used to deliver the supplement in the small to medium cartilage defect (less than 1 cm<sup>2</sup>). For implantation, supplement is delivered in the cartilage through the trochar at a density of 5 to 50 beads of 1 to 5 mm diameter. For example, 4 beads of 1 mm diameter are implanted in a traumatic cartilage lesion of 0.5 cm diameter and 1 mm depth diameter.

5

### Claims

1. A method of producing a hydrogel for intra-articular supplement comprising the steps of:
  - providing a solution of alginate,
  - providing a solution with chitosan having a Mw lower than 60 kDa,
  - mixing the solution of alginate and the solution of chitosan, wherein the mixed solution comprises between 0.5 and 0.7 % (w/v) of chitosan and between 1 and 1.4 % alginate (w/v),
  - introducing droplets of the mixed solution into a solution with Ca<sup>2+</sup> or Sr<sup>2+</sup> cations and
  - isolating gellified beads from the solution with cations.
2. The method according to claim 1, wherein said mixed solution comprises 0.6 % chitosan.
3. The method according to claim 1 or 2, wherein said mixed solution comprises 1.2 % alginate.
4. The method according to any one of claim 1 to 3, wherein alginate and chitosan in said mixed solution are present in a ratio between 1.75 and 2.25.
5. The method according to any one of claims 1 to 4, wherein said chitosan has a Mw of between 35 and 45 kDa.
6. The method according to any one of claims 1 to 5, wherein said droplets are passed through a needle to obtain a bead with a diameter between 0.01 and 5 mm.
7. The method according to any one of claims 1 to 6 wherein chitosan is of animal or vegetal origin.
8. A spherical hydrogel bead with a diameter between 0.01 and 5 mm, comprising a homogeneous mixture of alginate and chitosan of Mw lower than 60 kDa, **characterised in that** said bead comprises between 1 and 1.4 % alginate and between 0.5 and 0.7 % chitosan.
9. The bead according to claim 8, wherein said bead comprises 1.2 % alginate
10. The bead according to claim 8 or 9, wherein said bead comprises 0.6 % chitosan.
11. The bead according to any one of claims 8 to 10, wherein the chitosan has a Mw between 35 and 45 kDa.
12. The bead according to any of claims 8 to 11, for use in intra-articular supplementation.
13. An intra-articular supplement comprising spherical hydrogel beads according to claim 8.
14. An intra-articular supplement according to claim 13 further comprising a viscous thermogelling gel.
15. An intra-articular supplement according to any one of claims 13 to 14 wherein chitosan is of animal or of vegetal origin.
16. An intra-articular supplement according to any one of claims 13 to 15 further comprising a component selected from the group consisting of non-steroidal anti-inflammatory drug, anaesthetic, opioid analgesics, corticosteroids, anti-neoplastic, monoclonal antibodies, chimeric monoclonal antibodies, vitamins, minerals, nutraceuticals.
17. A supplementation device containing the hydrogel beads according to any one of claims 8 to 11.

55

**INTRAARTIKULÆRT SUPPLEMENT TIL ANVENDELSE TIL BEHANDLING AF  
LEDSYGDOMME OG -SKADER**

Patentkrav:

5

1. Fremgangsmåde til fremstilling af en hydrogel til intraartikulært supplement, hvilken fremgangsmåde omfatter følgende trin:

- tilvejebringelse af en opløsning af alginat,
- tilvejebringelse af en opløsning med chitosan, som har en molekylvægt på mindre end 60 kDa,
- blanding af opløsningen af alginat og opløsningen af chitosan, hvor den blandede opløsning omfatter mellem 0,5 og 0,7 % (vægt/volumen) af chitosan og mellem 1 og 1,4 % (vægt/volumen) af alginat,
- indføring af dråber af den blandede opløsning i en opløsning med Ca<sup>2+</sup>- eller Sr<sup>2+</sup>-kationer og
- isolering af gelerede perler fra opløsningen med kationer.

10

15

2. Fremgangsmåde ifølge krav 1, hvor den blandede opløsning omfatter 0,6 % chitosan.

20

3. Fremgangsmåde ifølge krav 1 eller 2, hvor den blandede opløsning omfatter 1,2 % alginat.

25

4. Fremgangsmåde ifølge et hvilket som helst af kravene 1-3, hvor alginat og chitosan i den blandede opløsning forefindes i et forhold på mellem 1,75 og 2,25.

5. Fremgangsmåde ifølge et hvilket som helst af kravene 1-4, hvor chitosanet har en molekylvægt på mellem 35 og 45 kDa.

30

6. Fremgangsmåde ifølge et hvilket som helst af kravene 1-5, hvor dråberne ledes gennem en kanyle for at opnå en perle med en diameter på mellem 0,01 og 5 mm.

7. Fremgangsmåde ifølge et hvilket som helst af kravene 1-6, hvor chitosan er af animalsk eller vegetabilsk oprindelse.

- 5 8. Kugleformet hydrogelerle med en diameter på mellem 0,01 og 5 mm, hvilken hydrogelerle omfatter en homogen blanding af alginat og chitosan med en molekylvægt på mindre end 60 kDa, kendetegnet ved, at perlen omfatter mellem 1 og 1,4 % alginat og mellem 0,5 og 0,7 % chitosan.
9. Perle ifølge krav 8, hvor perlen omfatter 1,2 % alginat.
- 10 10. Perle ifølge krav 8 eller 9, hvor perlen omfatter 0,6 % chitosan.
11. Perle ifølge et hvilket som helst af kravene 8-10, hvor chitosanet har en molekylvægt på mellem 35 og 45 kDa.
- 15 12. Perle ifølge et hvilket som helst af kravene 8-11 til anvendelse til intraartikulær supplering.
13. Intraartikulært supplement, som omfatter kugleformede hydrogelerler ifølge krav 8.
- 20 14. Intraartikulært supplement ifølge krav 13, som endvidere omfatter en viskøs termogelerende gel.
- 25 15. Intraartikulært supplement ifølge et hvilket som helst af kravene 13-14, hvor chitosan er af animalsk eller vegetabilsk oprindelse.
- 30 16. Intraartikulært supplement ifølge et hvilket som helst af kravene 13-15, som endvidere omfatter en bestanddel valgt fra gruppen bestående af non-steroidt antiinflammatorisk lægemiddel, anæstetikum, opioidanalgetika, kortikosteroider, antineoplastikum, monoklonale antistoffer, kimære monoklonale antistoffer, vitaminer, mineraler og nutraceutika.
17. Suppleringsanordning, som indeholder hydrogelerlerne ifølge et hvilket som helst af kravene 8-11.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5